A live podcast, roundtable discussion on radioligands was moderated by Brian Rini, MD of Vanderbilt-Ingram Cancer Center, and featured panelists Karen Autio, MD, and Michael Morris, MD, of Memorial Sloan Kettering Cancer Center, Gary T. Smith, MD, of Vanderbilt University Medical Center, and Tanya Dorff, MD, of City of Hope. In part one, the panelists review the latest developments in prostate cancer, with a focus on data presented at the 2024 European Society for Medical Oncology Congress, including SPLASH results, which explored the efficacy of Lutetium-177-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer. ...